| Bioactivity | SARS-CoV-IN-5 (compound 49) is a highly selective, nonpeptidic and noncovalent 3CLpro inhibitor with IC50s of 38 nM, 21.1 nM and 86 nM for 3CLpro of SARS-CoV-1, SARS-CoV-2, Bat coronavirus WIV1, respectively. SARS-CoV-IN-5 inhibits the replication of the SARS-CoV-2 delta variant with EC50 of 0.272 μM. SARS-CoV-IN-5 significantly reduces the lung viral copies in a K18-hACE2 transgenic mouse model. SARS-CoV-IN-5 has good target-specific and potential broad-spectrum anticoronavirus activities against SARS-CoV-1, WIV1, MERS, HCoV-OC43, HCoV-229E, and HKU9[1]. |
| Invitro | SARS-CoV-2-IN-96 对 MERS-CoV (IC50=1.68 μM)、HCoV-OC43 (IC50=0.94μM)、HCoV-229E (IC50=2.56 μM)、以及蝙蝠冠状病毒 HKU9 (IC50=0.402 μM) 的 3CLpro 均表现出中等抑制作用[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> SARS-CoV-IN-5 相关抗体: |
| Formula | C28H30BrFN6O5 |
| Molar Mass | 629.48 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhidong Jiang, et al. Discovery of Novel Nonpeptidic and Noncovalent Small Molecule 3CLpro Inhibitors as anti-SARS-CoV-2 Drug Candidate. J Med Chem. 2024 Aug 8;67(15):12760-12783. |